Bioreducible Nanocapsules for Folic Acid-Assisted Targeting and Effective Tumor-Specific Chemotherapy [Corrigendum]

Yi Q, Ma J, Kang K, Gu Z. Int J Nanomedicine. 2018;13:653—667.

The authors have advised that the Figure 4 caption on page 661 needs correction and the HE image of the Saline group in Figure 9 on page 666 was incorrectly placed due to an oversight during the process of compiling the data into a figure. This error resulted in its duplication with the HE image of the DOX/Z-NCs group in the same figure.

The updated Figure 4 caption should read as follows.

Figure 4 Flow cytometry results of time-dependent DOX signal changes.Notes: The experimental procedure commenced with a long duration of 24 hours (B), followed subsequently by a period of 2 hours (A), and both segments terminated simultaneously at the zero-hour mark. To ensure comparability between data from the two time points, a control group consisting of untreated cells (without any DOX-containing formulations) was utilized.

The correct Figure 9 is as follows.

Figure 9 HE staining of tissues of major organs (heart, liver, spleen, lung, kidney; ×100). Abbreviations: DOX, doxorubicin; DOX·HCl, doxorubicin hydrochloride; FA, folic acid; HE, Hematoxylin and Eosin; NCs, nanocapsules. Notes: For the DOX·HCl group: black arrows point out granular degeneration of the cardiac muscles and the black line marks laminar necrosis of liver cells. For the saline group: the black arrows point out diffuse hepatic necrosis and nucleus dissolution necrosis in the liver and inflammatory cell infiltration in the lung; the blue arrows point out tumor cell metastasis into the lung. Scale bar measures 100 μm.

The authors apologise for these errors.